{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:40:35Z","timestamp":1780519235011,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00105-022-05056-8","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T13:04:40Z","timestamp":1663160680000},"page":"809-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gerinnungsst\u00f6rungen bei Tumorerkrankungen","Cancer-associated coagulation disorders"],"prefix":"10.1007","volume":"73","author":[{"given":"Minna","family":"Voigtl\u00e4nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"5056_CR1","volume-title":"Klinische Angiologie","author":"F Langer","year":"2021","unstructured":"Langer\u00a0F (2021) Malignomassoziierte ven\u00f6se Thromboembolie. In: Klinische Angiologie. Springer, Berlin Heidelberg"},{"issue":"10","key":"5056_CR2","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge\u00a0D et\u00a0al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566\u2013e581","journal-title":"Lancet Oncol"},{"issue":"5","key":"5056_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key\u00a0NS et\u00a0al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"4","key":"5056_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman\u00a0GH et\u00a0al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974","journal-title":"Blood Adv"},{"issue":"10","key":"5056_CR5","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana\u00a0AA et al (2008) Development and validation of a\u00a0predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"8","key":"5056_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier\u00a0M et\u00a0al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N\u00a0Engl J Med 380(8):711\u2013719","journal-title":"N Engl J Med"},{"issue":"8","key":"5056_CR7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana\u00a0AA et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N\u00a0Engl J Med 380(8):720\u2013728","journal-title":"N Engl J Med"},{"key":"5056_CR8","unstructured":"Riess H et\u00a0al (2020) Thromboembolien bei Tumorpatienten. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/thromboembolien-bei-tumorpatienten-frueher-venoese-thromboembolien-vte-bei-tumorpatienten\/@@guideline\/html\/index.html. Zugegriffen: 23. Jan. 2022"},{"issue":"3","key":"5056_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MBC.0000000000000413","volume":"27","author":"NM Tun","year":"2016","unstructured":"Tun\u00a0NM, Guevara\u00a0E, Oo\u00a0TH (2016) Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a\u00a0systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 27(3):270\u2013274","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"5056_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cancers12010191","volume":"12","author":"D Fotiou","year":"2020","unstructured":"Fotiou\u00a0D, Gavriatopoulou\u00a0M, Terpos\u00a0E (2020) Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers 12(1):191","journal-title":"Cancers"},{"issue":"17","key":"5056_CR11","first-page":"599","volume":"82","author":"G Agnelli","year":"2020","unstructured":"Agnelli\u00a0G et\u00a0al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N\u00a0Engl J Med 82(17):599\u2013607","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"5056_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young\u00a0AM et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a\u00a0randomized trial (SELECT-D). J\u00a0Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"issue":"7","key":"5056_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob\u00a0GE et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N\u00a0Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"key":"5056_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","volume":"157","author":"L Jara-Palomares","year":"2017","unstructured":"Jara-Palomares\u00a0L et al (2017) Tinzaparin in cancer associated thrombosis beyond 6\u00a0months: TiCAT study. Thromb Res 157:90\u201396","journal-title":"Thromb Res"},{"issue":"10","key":"5056_CR15","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1111\/jth.15435","volume":"19","author":"L Caiano","year":"2021","unstructured":"Caiano\u00a0L et al (2021) Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: a systematic review and meta-analysis. J\u00a0Thromb Haemost 19(10):2468\u20132479","journal-title":"J Thromb Haemost"},{"issue":"4","key":"5056_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides\u00a0SV et\u00a0al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart\u00a0J 41(4):543\u2013603","journal-title":"Eur Heart J"},{"issue":"6","key":"5056_CR17","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens\u00a0SM et\u00a0al (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):e545\u2013e608","journal-title":"Chest"},{"issue":"2","key":"5056_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane\u00a0RD 2nd et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J\u00a0Thromb Haemost 18(2):411\u2013421","journal-title":"J Thromb Haemost"},{"issue":"6","key":"5056_CR19","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.3390\/curroncol28060453","volume":"28","author":"M Carrier","year":"2021","unstructured":"Carrier\u00a0M et al (2021) Treatment algorithm in cancer-associated thrombosis: updated Canadian expert consensus. Curr Oncol 28(6):5434\u20135451","journal-title":"Curr Oncol"},{"issue":"2","key":"5056_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejvs.2021.04.015","volume":"62","author":"R Bauersachs","year":"2021","unstructured":"Bauersachs\u00a0R et al (2021) Management and outcomes of patients with isolated superficial vein thrombosis under real life conditions (INSIGHTS-SVT). Eur J Vasc Endovasc Surg 62(2):241\u2013249","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"8","key":"5056_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1056\/NEJM199908193410807","volume":"341","author":"M Levi","year":"1999","unstructured":"Levi\u00a0M, Ten\u00a0HC (1999) Disseminated intravascular coagulation. N\u00a0Engl J Med 341(8):586\u2013592","journal-title":"N Engl J Med"},{"issue":"9","key":"5056_CR22","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1111\/jth.14946","volume":"18","author":"A Squizzato","year":"2020","unstructured":"Squizzato\u00a0A et\u00a0al (2020) Underlying disorders of disseminated intravascular coagulation: communication from the ISTH SSC subcommittees on disseminated Intravascular coagulation and Perioperative and critical care thrombosis and Hemostasis. J\u00a0Thromb Haemost 18(9):2400\u20132407","journal-title":"J Thromb Haemost"},{"issue":"1","key":"5056_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/2052-0492-2-15","volume":"2","author":"H Wada","year":"2014","unstructured":"Wada\u00a0H, Matsumoto\u00a0T, Yamashita\u00a0Y (2014) Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. j intensive care 2(1):15","journal-title":"j intensive care"},{"issue":"Suppl 1","key":"5056_CR24","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.thromres.2018.01.016","volume":"164","author":"M Levi","year":"2018","unstructured":"Levi\u00a0M (2018) Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thromb Res 164(Suppl 1):S77\u2013S81","journal-title":"Thromb Res"},{"issue":"5","key":"5056_CR25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1055\/s-0037-1616068","volume":"86","author":"FB Taylor Jr.","year":"2001","unstructured":"Taylor\u00a0FB Jr. et\u00a0al (2001) Towards definition, clinical and laboratory criteria, and a\u00a0scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327\u20131330","journal-title":"Thromb Haemost"},{"issue":"8","key":"5056_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1182\/blood-2017-10-804096","volume":"131","author":"M Levi","year":"2018","unstructured":"Levi\u00a0M, Scully\u00a0M (2018) How I treat disseminated intravascular coagulation. Blood 131(8):845\u2013854","journal-title":"Blood"},{"issue":"2","key":"5056_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/a-1393-8302","volume":"41","author":"H Ten Cate","year":"2021","unstructured":"Ten Cate\u00a0H, Leader\u00a0A (2021) Management of disseminated Intravascular coagulation in acute leukemias. Hamostaseologie 41(2):120\u2013126","journal-title":"Hamostaseologie"},{"issue":"5","key":"5056_CR28","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1160\/TH15-09-0740","volume":"115","author":"A Squizzato","year":"2016","unstructured":"Squizzato\u00a0A et\u00a0al (2016) Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost 115(5):896\u2013904","journal-title":"Thromb Haemost"},{"issue":"2","key":"5056_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5482\/HAMO-13-08-0046","volume":"34","author":"A Biswas","year":"2014","unstructured":"Biswas\u00a0A et\u00a0al (2014) Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 34(2):160\u2013166","journal-title":"Hamostaseologie"},{"issue":"6","key":"5056_CR30","first-page":"701","volume":"112","author":"T Iba","year":"2021","unstructured":"Iba\u00a0T et\u00a0al (2021) Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Med 112(6):701\u2013712","journal-title":"Minerva Med"},{"issue":"21","key":"5056_CR31","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMra1601561","volume":"375","author":"FW Leebeek","year":"2016","unstructured":"Leebeek\u00a0FW, Eikenboom\u00a0JC (2016) Von Willebrand\u2019s Disease. N\u00a0Engl J Med 375(21):2067\u20132080","journal-title":"N Engl J Med"},{"issue":"12","key":"5056_CR32","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi\u00a0A, Barbui\u00a0T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95(12):1599\u20131613","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"5056_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/10428199609074364","volume":"22","author":"PJ van Genderen","year":"1996","unstructured":"van Genderen\u00a0PJ et\u00a0al (1996) Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 22(Suppl 1):79\u201382","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"5056_CR34","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3324\/haematol.2020.255117","volume":"105","author":"M Franchini","year":"2020","unstructured":"Franchini\u00a0M, Mannucci\u00a0PM (2020) Acquired von Willebrand syndrome: focused for hematologists. Haematologica 105(8):2032\u20132037","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"5056_CR35","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0049-3848(13)70003-3","volume":"130","author":"A Tiede","year":"2012","unstructured":"Tiede\u00a0A (2012) Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res 130(Suppl 2):S2\u20136","journal-title":"Thromb Res"},{"issue":"4","key":"5056_CR36","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1046\/j.1365-2141.1997.4823285.x","volume":"99","author":"PJ van Genderen","year":"1997","unstructured":"van Genderen\u00a0PJ et al (1997) Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 99(4):832\u2013836","journal-title":"Br J Haematol"},{"issue":"25","key":"5056_CR37","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","volume":"117","author":"A Tiede","year":"2011","unstructured":"Tiede\u00a0A et\u00a0al (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777\u20136785","journal-title":"Blood"},{"issue":"6","key":"5056_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1055\/s-2006-949663","volume":"32","author":"JJ Michiels","year":"2006","unstructured":"Michiels\u00a0JJ et al (2006) Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 32(6):577\u2013588","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"5056_CR39","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","volume":"92","author":"AB Federici","year":"1998","unstructured":"Federici\u00a0AB et\u00a0al (1998) Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 92(8):2707\u20132711","journal-title":"Blood"},{"issue":"6","key":"5056_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00277-016-2650-x","volume":"95","author":"C Dicke","year":"2016","unstructured":"Dicke\u00a0C et\u00a0al (2016) Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. Ann Hematol 95(6):945\u2013957","journal-title":"Ann Hematol"},{"issue":"7","key":"5056_CR41","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","volume":"105","author":"A Tiede","year":"2020","unstructured":"Tiede\u00a0A et\u00a0al (2020) International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 105(7):1791\u20131801","journal-title":"Haematologica"},{"issue":"7","key":"5056_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1055\/s-0034-1390004","volume":"40","author":"A Tiede","year":"2014","unstructured":"Tiede\u00a0A, Werwitzke\u00a0S, Scharf\u00a0RE (2014) Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost 40(7):803\u2013811","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"5056_CR43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1171-0522","volume":"41","author":"A Tiede","year":"2021","unstructured":"Tiede\u00a0A (2021) Critical bleeding in acquired hemophilia A: bypassing agents or recombinant porcine factor VIII? Hamostaseologie 41(4):240\u2013245","journal-title":"Hamostaseologie"},{"issue":"3","key":"5056_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jth.15208","volume":"19","author":"A Tiede","year":"2021","unstructured":"Tiede\u00a0A, Kemkes-Matthes\u00a0B, Knobl\u00a0P (2021) Should emicizumab be used in patients with acquired hemophilia A? J\u00a0Thromb Haemost 19(3):637\u2013644","journal-title":"J Thromb Haemost"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-05056-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T16:04:38Z","timestamp":1664208278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-05056-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5056"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-05056-8","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"14 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.\u00a0Voigtl\u00e4nder<\/b>: A.\u00a0Finanzielle Interessen: Erstattung von Reise- und \u00dcbernachtungskosten im Rahmen von Fortbildungen und Jahrestagungen durch folgende Firmen: Bayer, Bristol-Myers Squibb, CSL Behring, LEO Pharma. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellte Fach\u00e4rztin in der II.\u00a0Medizinischen Klinik und Poliklinik des Universit\u00e4tsklinikums Hamburg-Eppendorf | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie, Gesellschaft f\u00fcr Thrombose- und H\u00e4mostaseforschung. <b>F.\u00a0Langer<\/b>: A.\u00a0Finanzielle Interessen: Drittmittel zur Unterst\u00fctzung patientennaher Forschungsprojekte: Bayer, Chugai, CSL Behring, Intersero, Novo Nordisk, Pfizer, SOBI.\u00a0\u2013 Pers\u00f6nliche Honorare f\u00fcr Vortragst\u00e4tigkeit, inklusive Erstattung von Reise- und \u00dcbernachtungskosten: Alexion, Aspen, Bayer, Boehringer Ingelheim, BMS, Chugai, CSL Behring, Daiichi Sankyo, Grifols, Janssen-Cilag, LEO Pharma, Mitsubishi Tanabe Pharma, Novo Nordisk, Octapharma, Pfizer, Sanofi, Shire, Siemens, SOBI, Stago, Werfen, Viatris. \u2013\u00a0Pers\u00f6nliche Honorare f\u00fcr Beratert\u00e4tigkeit, inklusive Erstattung von Reise- und \u00dcbernachtungskosten: Ablynx, Alexion, Aspen, Bayer, BioMarin, Boehringer Ingelheim, BMS, Chugai, CSL Behring, Daiichi Sankyo, LEO Pharma, Mitsubishi Tanabe Pharma, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, SOBI, Takeda, Viatris.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Facharzt am Universit\u00e4tsklinikum Hamburg-Eppendorf, II.\u00a0Medizinische Klinik und Poliklinik, Mitglied und Sekret\u00e4r der Gesellschaft f\u00fcr Thrombose- und H\u00e4mostaseforschung (GTH e.\u202fV.) | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie (DGHO e.\u202fV.), International Society on Thrombosis and Haemostasis (ISTH), Berufsverband der Deutschen H\u00e4mostaseologen (BDH e.\u202fV.), Deutsche H\u00e4mophiliegesellschaft (DHG e.\u202fV.), Interessengemeinschaft H\u00e4mophiler (IGH e.\u202fV.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}